Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
Status:
Suspended
Trial end date:
2022-01-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cabozantinib, nivolumab, and ipilimumab work in treating
patients with differentiated thyroid cancer that does not respond to radioactive iodine and
that worsened after treatment with a drug targeting the vascular endothelial growth factor
receptor (VEGFR), a protein needed to form blood vessels. Cabozantinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with
monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system
attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Giving cabozantinib, nivolumab and ipilimumab may work better than the usual approach
consisting of chemotherapy with drugs such as doxorubicin, sorafenib, and lenvatinib for this
type of thyroid cancer.